ZURICH, October 21, 2013 /PRNewswire/ --
Cytos Biotechnology Ltd (SIX:CYTN) ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003. This study investigates the effectiveness, safety and tolerability of CYT003 in patients with moderate to severe allergic asthma not controlled on their standard treatment.
Based on the completion of the enrolment of this study, Cytos will call the second tranche of the convertible loan notes in the amount of CHF 6.625 million from Abingworth, venBio, Aisling and Amgen, which was part of the investment by this syndicate of investors in May 2012.
Dr. Christian Itin, Chairman and CEO of Cytos, said: "We are pleased with the progress of our Phase 2b study in patients with moderate to severe allergic asthma. The study is on track and we expect topline data from the study to be available in the second quarter of 2014."
About Cytos Biotechnology Ltd
Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a novel, first-in-class, immune modulator in Phase 2 clinical development as a potential new treatment for asthma. CYT003 has a novel mechanism of action that inhibits the immune response that causes asthma, and may therefore be beneficial for the control of asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function in patients with persistent allergic asthma despite withdrawal of standard therapy with inhaled corticosteroids. CYT003 has been shown to have a good safety and tolerability profile in more than 450 individuals receiving the active agent so far.
Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.
Help employers find you! Check out all the jobs and post your resume.